Taiwan
· Delayed Price · Currency is TWD PharmaEngine Statistics
Total Valuation
PharmaEngine has a market cap or net worth of TWD 11.35 billion. The enterprise value is 5.69 billion.
| Market Cap | 11.35B |
| Enterprise Value | 5.69B |
Important Dates
The next estimated earnings date is Tuesday, July 29, 2025.
| Earnings Date | Jul 29, 2025 |
| Ex-Dividend Date | Aug 12, 2024 |
Share Statistics
PharmaEngine has 143.68 million shares outstanding. The number of shares has increased by 0.16% in one year.
| Current Share Class | 143.68M |
| Shares Outstanding | 143.68M |
| Shares Change (YoY) | +0.16% |
| Shares Change (QoQ) | -0.33% |
| Owned by Insiders (%) | 1.25% |
| Owned by Institutions (%) | 5.97% |
| Float | 93.43M |
Valuation Ratios
The trailing PE ratio is 6.42.
| PE Ratio | 6.42 |
| Forward PE | n/a |
| PS Ratio | 4.46 |
| PB Ratio | 2.06 |
| P/TBV Ratio | 2.06 |
| P/FCF Ratio | 5.21 |
| P/OCF Ratio | 5.20 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 2.73, with an EV/FCF ratio of 2.61.
| EV / Earnings | 3.21 |
| EV / Sales | 2.23 |
| EV / EBITDA | 2.73 |
| EV / EBIT | 2.74 |
| EV / FCF | 2.61 |
Financial Position
The company has a current ratio of 13.34, with a Debt / Equity ratio of 0.00.
| Current Ratio | 13.34 |
| Quick Ratio | 13.29 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | 0.00 |
| Debt / FCF | 0.00 |
| Interest Coverage | 13,923.34 |
Financial Efficiency
Return on equity (ROE) is 37.50% and return on invested capital (ROIC) is 27.39%.
| Return on Equity (ROE) | 37.50% |
| Return on Assets (ROA) | 25.89% |
| Return on Invested Capital (ROIC) | 27.39% |
| Return on Capital Employed (ROCE) | 37.66% |
| Revenue Per Employee | 57.87M |
| Profits Per Employee | 40.26M |
| Employee Count | 44 |
| Asset Turnover | 0.51 |
| Inventory Turnover | 2.00 |
Taxes
In the past 12 months, PharmaEngine has paid 416.52 million in taxes.
| Income Tax | 416.52M |
| Effective Tax Rate | 19.04% |
Stock Price Statistics
The stock price has decreased by -19.06% in the last 52 weeks. The beta is 0.26, so PharmaEngine's price volatility has been lower than the market average.
| Beta (5Y) | 0.26 |
| 52-Week Price Change | -19.06% |
| 50-Day Moving Average | 86.96 |
| 200-Day Moving Average | 94.19 |
| Relative Strength Index (RSI) | 30.41 |
| Average Volume (20 Days) | 574,186 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, PharmaEngine had revenue of TWD 2.55 billion and earned 1.77 billion in profits. Earnings per share was 12.31.
| Revenue | 2.55B |
| Gross Profit | 2.50B |
| Operating Income | 2.07B |
| Pretax Income | 2.19B |
| Net Income | 1.77B |
| EBITDA | 2.08B |
| EBIT | 2.07B |
| Earnings Per Share (EPS) | 12.31 |
Balance Sheet
The company has 5.67 billion in cash and 6.97 million in debt, giving a net cash position of 5.66 billion or 39.40 per share.
| Cash & Cash Equivalents | 5.67B |
| Total Debt | 6.97M |
| Net Cash | 5.66B |
| Net Cash Per Share | 39.40 |
| Equity (Book Value) | 5.50B |
| Book Value Per Share | 38.30 |
| Working Capital | 5.49B |
Cash Flow
In the last 12 months, operating cash flow was 2.18 billion and capital expenditures -502,000, giving a free cash flow of 2.18 billion.
| Operating Cash Flow | 2.18B |
| Capital Expenditures | -502,000 |
| Free Cash Flow | 2.18B |
| FCF Per Share | 15.18 |
Margins
Gross margin is 98.07%, with operating and profit margins of 81.48% and 69.58%.
| Gross Margin | 98.07% |
| Operating Margin | 81.48% |
| Pretax Margin | 85.94% |
| Profit Margin | 69.58% |
| EBITDA Margin | 81.54% |
| EBIT Margin | 81.48% |
| FCF Margin | 85.64% |
Dividends & Yields
This stock pays an annual dividend of 6.00, which amounts to a dividend yield of 7.59%.
| Dividend Per Share | 6.00 |
| Dividend Yield | 7.59% |
| Dividend Growth (YoY) | -25.00% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 12.16% |
| Buyback Yield | -0.16% |
| Shareholder Yield | 7.39% |
| Earnings Yield | 15.61% |
| FCF Yield | 19.21% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on July 26, 2017. It was a forward split with a ratio of 1.1999616012.
| Last Split Date | Jul 26, 2017 |
| Split Type | Forward |
| Split Ratio | 1.1999616012 |
Scores
PharmaEngine has an Altman Z-Score of 21.53 and a Piotroski F-Score of 6.
| Altman Z-Score | 21.53 |
| Piotroski F-Score | 6 |